Back to discover
Disease
Carcinoid Tumor
Late-stage therapeutic developmentEmerging research
1
Publications
18
Clinical trials
2008
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Research2008-05-01Journal of clinical oncology : official journal of the American Society of Clinical Oncology
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 5 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
- Q4 2026Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy
- Q3 2027A Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Paltusotine in Adults With Carcinoid Syndrome Due to Well-Differentiated Neuroendocrine Tumors
- Q1 2028A Phase II Study of Lenvatinib in Combination With Everolimus in Patients With Advanced Carcinoid Tumors
- Q2 2028Phase II Randomized Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa, or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR
- Q4 2028IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
Major developments
Upcoming trial readoutHigh impact
Results expected Q3 20272026-06-25
Upcoming trial readoutHigh impact
Results expected Q4 20262026-03-30
Clinical MilestonesViewHide
Results expected
- 2026-06-25A Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Paltusotine in Adults With Carcinoid Syndrome Due to Well-Differentiated Neuroendocrine TumorsResults expected Q3 2027
- 2026-06-25IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE CancersResults expected Q4 2028
- 2026-06-22Phase II Randomized Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa, or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABRResults expected Q2 2028
- 2026-03-30Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA TherapyResults expected Q4 2026
- 2026-03-19A Phase II Study of Lenvatinib in Combination With Everolimus in Patients With Advanced Carcinoid TumorsResults expected Q1 2028
Activity timeline5
- 2026-06-25ClinicalA Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Paltusotine in Adults With Carcinoid Syndrome Due to Well-Differentiated Neuroendocrine TumorsResults expected Q3 2027
- 2026-06-25ClinicalIMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE CancersResults expected Q4 2028
- 2026-06-22ClinicalPhase II Randomized Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa, or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABRResults expected Q2 2028
- 2026-03-30ClinicalPhase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA TherapyResults expected Q4 2026
- 2026-03-19ClinicalA Phase II Study of Lenvatinib in Combination With Everolimus in Patients With Advanced Carcinoid TumorsResults expected Q1 2028
Clinical trials
The current development programme across all trial phases.
Clinical programme
18
6
6
6
Late-stage studies
Recruiting
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Most influential
Leading journals1
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology1
Leading researchers8
- de Herder WW1
- Feelders RA1
- Kam BL1
- Kooij PP1
- Krenning EP1
- Kwekkeboom DJ1
- van Aken MO1
- van Eijck CH1
Affiliations (unnormalised)1
- Erasmus Medical Center1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182)
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.